Stefanie Maurer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8341136/publications.pdf

Version: 2024-02-01

1163117 1199594 14 264 8 12 citations h-index g-index papers 14 14 14 404 citing authors docs citations times ranked all docs

#	Article	IF	CITATIONS
1	Platelet-mediated shedding of NKG2D ligands impairs NK cell immune-surveillance of tumor cells. Oncolmmunology, 2018, 7, e1364827.	4.6	72
2	The Immune Checkpoint Modulator OX40 and Its Ligand OX40L in NK-Cell Immunosurveillance and Acute Myeloid Leukemia. Cancer Immunology Research, 2018, 6, 209-221.	3.4	49
3	Inhibition of NK Reactivity Against Solid Tumors by Platelet-Derived RANKL. Cancers, 2019, 11, 277.	3.7	28
4	Modulation of Immune Responses by Platelet-Derived ADAM10. Frontiers in Immunology, 2020, 11, 44.	4.8	26
5	The novel deubiquitinase inhibitor b-AP15 induces direct and NK cell-mediated antitumor effects in human mantle cell lymphoma. Cancer Immunology, Immunotherapy, 2018, 67, 935-947.	4.2	21
6	NK Cell Interaction With Platelets and Myeloid Cells in the Tumor Milieu. Frontiers in Immunology, 2020, 11, 608849.	4.8	16
7	Platelet-expressed immune checkpoint regulator GITRL in breast cancer. Cancer Immunology, Immunotherapy, 2021, 70, 2483-2496.	4.2	15
8	Suicide geneâ€'armed measles vaccine virus for the treatment of AML. International Journal of Oncology, 2019, 55, 347-358.	3.3	11
9	Platelet-Expressed TNFRSF13B (TACI) Predicts Breast Cancer Progression. Frontiers in Oncology, 2021, 11, 642170.	2.8	8
10	The BCR-ABL inhibitor nilotinib influences phenotype and function of monocyte-derived human dendritic cells. Cancer Immunology, Immunotherapy, 2018, 67, 775-783.	4.2	7
11	Controversial Role of the Immune Checkpoint OX40L Expression on Platelets in Breast Cancer Progression. Frontiers in Oncology, 0, 12 , .	2.8	4
12	The Deubiquitinase Inhibitor b-AP15 and Its Effect on Phenotype and Function of Monocyte-Derived Dendritic Cells. Neoplasia, 2019, 21, 653-664.	5.3	3
13	Regulation of Platelet-Derived ADAM17: A Biomarker Approach for Breast Cancer?. Diagnostics, 2021, 11, 1188.	2.6	3
14	CD18 Antibody Application Blocks Unwanted Off-Target T Cell Activation Caused by Bispecific Antibodies. Cancers, 2021, 13, 4596.	3.7	1